Valeria G. Nicolini

Schlieren, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.

Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.

Journal: Cancer research communications

Published: March 18, 2026

PD1-IL2v expands and induces effector CD8+ TILs, but not Tregs, in the BCG treated orthotopic non-muscle invasive bladder cancer model.

PD1-IL2v expands and induces effector CD8+ TILs, but not Tregs, in the BCG treated orthotopic non-muscle invasive bladder cancer model.

Journal: Journal of experimental & clinical cancer research : CR

Published: October 22, 2025

CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB.

CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB.

Journal: Antibodies (Basel, Switzerland)

Published: September 27, 2025

An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIII.

An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIII.

Journal: Journal of pharmaceutical sciences

Published: July 09, 2025

Novel immunodominant neoepitope in a KPC mouse model of pancreatic cancer allowing identification of tumor-specific T cells.

Novel immunodominant neoepitope in a KPC mouse model of pancreatic cancer allowing identification of tumor-specific T cells.

Journal: Oncoimmunology

Published: April 08, 2025

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Journal: Blood

Published: February 20, 2025

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.

Journal: Blood

Published: November 27, 2023

Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.

Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 05, 2023

Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.

Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 02, 2023

Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1.

Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1.

Journal: The AAPS journal

Published: March 31, 2023

Cell Squeeze: driving more effective CD8 T-cell activation through cytosolic antigen delivery.

Cell Squeeze: driving more effective CD8 T-cell activation through cytosolic antigen delivery.

Journal: Immuno-oncology technology

Published: August 31, 2022

Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1.

Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1.

Journal: The AAPS journal

Published: June 23, 2022

Showing 1-12 of 27

Last Updated: 09/26/2026